Skip to main content
. 2023 Aug 31;15(9):1855. doi: 10.3390/v15091855

Figure 3.

Figure 3

B2CNT for testing against SARS-CoV-2 variants BA.5 and XBB.1.5 at BSL-2. (A) Diagram of Bench-to-Clinics Neutralization Test (B2CNT) workflow. The schematic workflow was created with BioRender.com. (B) Infection rates after 16 h of infection with mGFP Δ3678_BA.5-spike or mGFP Δ3678_XBB.1.5-spike. (C) Analysis of the assay robustness. SD, standard deviations; Z’ > 0.5, suitable for high-throughput screening. (D) Correlation of mGFP Δ3678_BA.5-spike FRNT50 with PRNT50. PRNT50 was obtained with plaque assay using the USA-WA1/2020 containing BA.5-spike. The coefficient and p-values (two-tailed) calculated from a linear regression model are shown. (E) Ratios of FFRNT50 using mGFP Δ3678_BA.5-spike to PRNT50. The geometric mean is shown. The error bar indicates the 95% confidence interval of the geometric mean. (F) Correlation of mGFP Δ3678_XBB.1.5-spike FRNT50 with PRNT50. The coefficient and p-values (two-tailed) calculated from a linear regression model are shown. (G) Ratios of FFRNT50 of mGFP Δ3678_XBB.1.5-spike to PRNT50. The geometric mean is shown. The error bar indicates the 95% confidence interval of the geometric mean.